Is It Time To Buy Cannabis Stocks & ETFs?
In this episode of ETF Spotlight, I speak with Tim Seymour, CIO of Seymour Asset Management and co-host of CNBC's Fast Money, and Christian Magoon, CEO of Amplify ETFs. We discuss cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report), which is actively managed by Tim.
Major indexes have rebounded strongly from their March lows as investors have started looking past the grim economic data and the health crisis. Is there a disconnect between the economy and the stock market?
2019 was terrible for most pot stocks and the underperformance continued earlier this year, but many of them rebounded in late March. Is the worst over for pot stocks?
Cannabis shops were deemed essential services in many states and remained open during coronavirus related lockdowns. After some panic buying initially, sales have seen steady growth as consumption continues to rise.
Medical marijuana is legal in 33 states and in the District of Columbia, while recreational use is legal in 11 states and in the District of Columbia, but it remains illegal on the federal level. Should we expect any major changes in the regulatory landscape for marijuana?
GW Pharmaceuticals (GWPH - Free Report), Canopy Growth Corporation (CGC - Free Report). Cronos Group (CRON - Free Report) and Innovative Industrial Properties (IIPR - Free Report) are CNBS’s top holdings. IIPR, a cannabis-focused REIT, has done quite well this year. What do investors need to know about these companies?
We also talk about the Amplify Online Retail ETF (IBUY - Free Report) which is one of the top-performing ETFs this year. And we may see a permanent shift in consumer behavior toward online shopping even after the health crisis is over.
Disclaimer: Foreign exchange (Forex) trading carries a high level of risk and may not be suitable for all investors. The risk grows as the leverage is higher. Investment objectives, risk appetite and ...
more